Table 3.
MIC Range, MIC50, MIC90, and Susceptible Rate of C/T, C/A, M/V, and Colistin Against Pseudomonas aeruginosa Strains (n=150)
| Group of Strains/ Control Strain | Antibiotic | MIC Range (µg/mL) | MIC50 (µg/mL) | MIC90 (µg/mL) | MBC Range (µg/mL) | S |
|---|---|---|---|---|---|---|
| All clinical P. aeruginosa (n=150) |
Ceftolozane/tazobactam | 0.25–>256 | 2 | 64 | ND | 87% |
| Ceftazidime/awibactam | 1–>256 | 4 | 32 | ND | 88% | |
| Meropenem/vaborbactam | 0.125–256 | 8 | 64 | ND | 51% | |
| Colistin | 0.125–8 | 1 | 2 | ND | 98% | |
| Group I (n=22) |
Ceftolozane/tazobactam | 0.5–2 | 1 | 1 | ND | 100% |
| Ceftazidime/awibactam | 1–4 | 2 | 2 | ND | 100% | |
| Meropenem/vaborbactam | 0.125–4 | 0.25 | 2 | ND | 100% | |
| Colistin | 0.5–8 | 1 | 2 | ND | 91% | |
| Group II (n=40) |
Ceftolozane/tazobactam | 0.25–>256 | 1 | 2 | ND | 95% |
| Ceftazidime/awibactam | 1–256 | 2 | 8 | ND | 95% | |
| Meropenem/vaborbactam | 0.25–64 | 8 | 16 | ND | 78% | |
| Colistin | 0.125–4 | 1 | 2 | ND | 98% | |
| Group III (n=67) |
Ceftolozane/tazobactam | 0.5–>256 | 2 | 4 | ND | 93% |
| Ceftazidime/awibactam | 1–>256 | 4 | 8 | ND | 96% | |
| Meropenem/vaborbactam | 0.125–64 | 16 | 32 | ND | 22% | |
| Colistin | 0.25–2 | 1 | 2 | ND | 100% | |
| Group IV (n=13) |
Ceftolozane/tazobactam | 256–>256 | 256 | >256 | ND | 0% |
| Ceftazidime/awibactam | 16–>256 | 64 | 256 | ND | 0% | |
| Meropenem/vaborbactam | 32–256 | 256 | 256 | ND | 0% | |
| Colistin | 0.5–2 | 1 | 2 | ND | 100% | |
| Group V (n=8) |
Ceftolozane/tazobactam | 1–8 | 2 | 2 | ND | 100% |
| Ceftazidime/awibactam | 2–8 | 2 | 8 | ND | 100% | |
| Meropenem/vaborbactam | 0.125–1 | 0.25 | 1 | ND | 100% | |
| Colistin | 0.5–2 | 1 | 2 | ND | 100% | |
| P. aeruginosa ATCC 27853 | Ceftolozane/tazobactam | 0.75 | – | – | ND | – |
| Ceftazidime/awibactam | 0.75 | – | – | ND | – | |
| Meropenem/vaborbactam | 0.25 | – | – | ND | – | |
| Colistin | 0.25 | – | – | ND | – |
Abbreviations: ND, not determined; S, susceptible strains.